HYMPAVZI PEN (marstacimab-hncq)
ANTIHEMOPHILIC PRODUCTS · HEMOPHILIA A ·+1
Laboratories Div
Drug class
Antihemophilic Products
Antihemophilic products are a class of therapeutic biologics comprising plasma-derived and recombinant coagulation factor VIII concentrates, as well as extended half-life factor variants. Read more about Antihemophilic Products
33 drugs in this class 14 manufacturers
Drugs in Antihemophilic Products
ALHEMO PEN (concizumab-mtci)
ANTIHEMOPHILIC PRODUCTS · BLEEDING PREVENTION IN HEREDITARY FACTOR VIII DEFICIENCY ·+1
NOVO NORDISK
HEMOFIL M (antihemophilic factor, human)
ANTIHEMOPHILIC PRODUCTS · HEMOPHILIA A ·+2
Takeda Pharmaceuticals America
JIVI (antihemophilic factor (FVIII) rec, B-domain deleted peg-aucl)
ANTIHEMOPHILIC PRODUCTS · HEMOPHILIA A ·+2
Bayer HealthCare
QFITLIA (fitusiran sodium)
ANTIHEMOPHILIC PRODUCTS · BLEEDING PREVENTION IN HEREDITARY FACTOR VIII DEFICIENCY ·+1
GENZYME
QFITLIA PEN (fitusiran sodium)
ANTIHEMOPHILIC PRODUCTS · BLEEDING PREVENTION IN HEREDITARY FACTOR VIII DEFICIENCY ·+1
GENZYME
Filter & compare in the drug finder →
Opens the drug finder with Antihemophilic Products preselected. Add indication or manufacturer filters there.
Antihemophilic products are a class of therapeutic biologics comprising plasma-derived and recombinant coagulation factor VIII concentrates, as well as extended half-life factor variants.
They function primarily through factor replacement therapy, substituting for missing or dysfunctional endogenous factor VIII to serve as an essential cofactor in activating factor X within the intrinsic coagulation cascade and restoring effective hemostasis.
These agents are indicated primarily for the on-demand control of bleeding, routine prophylaxis, and perioperative management in individuals with hemophilia A, with certain plasma-derived formulations also indicated for select types of von Willebrand disease.
-
fda.gov
Antihemophilic products are a class of therapeutic biologics comprising plasma-derived and recombinant coagulation factor VIII concentrates, as well as extended half-life factor variants
-
nih.gov
Antihemophilic products are a class of therapeutic biologics comprising plasma-derived and recombinant coagulation factor VIII concentrates, as well as extended half-life factor variants
-
drugbank.com
They function primarily through factor replacement therapy, substituting for missing or dysfunctional endogenous factor VIII to serve as an essential cofactor in activating factor X within the intrinsic coagulation cascade and restoring effective hemostasis
-
fda.gov
These agents are indicated primarily for the on-demand control of bleeding, routine prophylaxis, and perioperative management in individuals with hemophilia A, with certain plasma-derived formulations also indicated for select types of von Willebrand disease
-
fda.gov
These agents are indicated primarily for the on-demand control of bleeding, routine prophylaxis, and perioperative management in individuals with hemophilia A, with certain plasma-derived formulations also indicated for select types of von Willebrand disease
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.